文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

不同疫苗及基础疾病的新型冠状病毒奥密克戎变异株感染患者临床特征分析

[Analysis of clinical characteristics of patients with different vaccines and underlying diseases infected with novel coronavirus Omicron variant].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论在合并基础疾病的奥密克戎感染者中,腺病毒疫苗组康复一周后IgG抗体滴度高于灭活疫苗组,其余临床结局两组无显著差异。

该研究收集2022年1月21日至3月7日天津市第一中心医院收治的430例新型冠状病毒奥密克戎变异株感染患者数据,选取其中108例合并基础疾病者,按接种疫苗类型分为灭活疫苗组(93例)和腺病毒疫苗组(15例)。两组在性别、年龄、BMI、疾病类型、是否完成全程接种、是否序贯加强及基础疾病方面无统计学显著差异;临床症状、血常规、生化指标、C反应蛋白、胸部CT影像、住院天数、核酸转阴时间、是否入住ICU、核酸复阳及IgM抗体滴度表达均无统计学显著差异;腺病毒疫苗组IgG抗体滴度高于灭活疫苗组(229.67±26.13 g/L vs. 194.33±61.56 g/L,P=0.020)。在接种加强针的患者中,两疫苗组实验室检查、住院天数、核酸转阴时间、核酸复阳及新型冠状病毒抗体滴度表达也无显著差异。结论认为,在合并基础疾病的奥密克戎变异株感染患者中,灭活病毒疫苗的保护作用与腺病毒疫苗相当,腺病毒疫苗接种者康复一周后IgG抗体滴度高于灭活病毒疫苗接种者。

要点

  • 合并基础疾病的奥密克戎感染者中,腺病毒疫苗组康复一周后IgG抗体滴度高于灭活疫苗组(229.67±26.13 g/L vs. 194.33±61.56 g/L,P=0.020)。
  • 两组住院天数、核酸转阴时间、是否入住ICU、核酸复阳及IgM抗体滴度表达均无统计学显著差异。
  • 两组临床症状(发热、干咳、咽痛、流涕等)、血常规、生化指标、CRP水平及胸部CT影像结果均无统计学显著差异。
  • 接种加强针的患者中,灭活疫苗组与腺病毒疫苗组实验室检查、住院天数、核酸转阴时间、核酸复阳及抗体滴度表达也无显著差异。
  • 108例合并基础疾病的奥密克戎感染者中,93例接种灭活疫苗,15例接种腺病毒疫苗。

适用人群与场景

  • 2022年1月21日至3月7日天津市第一中心医院收治的430例新型冠状病毒奥密克戎变异株感染患者中,选取的108例合并基础疾病者。

研究设计与关键结果

  • 研究类型为临床特征分析,纳入108例合并基础疾病的奥密克戎变异株感染患者,其中灭活疫苗组93例、腺病毒疫苗组15例。
  • 两组性别、年龄、BMI、疾病类型、是否完成全程接种、是否序贯加强及基础疾病均无统计学显著差异。
  • 两组临床症状(发热、干咳、咽痛、流涕等)无统计学显著差异;血常规、生化指标、CRP水平及胸部CT影像结果均无统计学显著差异。
  • 两组住院天数、核酸转阴时间、是否入住ICU、核酸复阳及IgM抗体滴度表达均无统计学显著差异。
  • 腺病毒疫苗组IgG抗体滴度高于灭活疫苗组(229.67±26.13 g/L vs. 194.33±61.56 g/L,P=0.020)。
  • 接种加强针的患者中,灭活疫苗组与腺病毒疫苗组实验室检查、住院天数、核酸转阴时间、核酸复阳及新型冠状病毒抗体滴度表达均无显著差异。

证据类型、等级与局限

  • 证据类型:临床特征分析(研究论文)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在合并基础疾病的奥密克戎变异株感染患者中,灭活病毒疫苗的保护作用与腺病毒疫苗相当,腺病毒疫苗接种者康复一周后IgG抗体滴度高于灭活病毒疫苗接种者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the clinical characteristics of patients inoculated with different vaccines and underlying diseases, infected with the novel coronavirus Omicron variant.

METHODS: The data of 430 patients infected with the novel coronavirus Omicron variant who were admitted to Tianjin First Center Hospital from January 21, 2022 to March 7, 2022 were collected. A total of 108 patients with Omicron variant infection with underlying diseases were selected and enrolled. The gender, age, body mass index (BMI), history of underlying diseases, vaccination status (vaccination times, vaccination type), clinical symptoms, laboratory test indicators, imaging data, hospitalization time, nucleic acid negative conversion time, re-positivity and antibody titer from the two groups of the patients were collected and analyzed.

RESULTS: In the 108 patients, 93 cases received inactivated vaccine and 15 cases received adenovirus vaccine. There was no statistically significant difference between the two groups in terms of gender, age, BMI, disease types, whether completed the fully vaccinated, whether had prime boost and underlying diseases. Both groups had fever, dry cough, sore throat, runny nose and other clinical symptoms, but there were no statistical difference between the two groups. There were no statistically significant differences in laboratory blood routine tests, biochemical indexes, C-reactive protein (CRP) level and the results of chest computed tomography (CT) imaging between the two groups. There were no statistically significant differences in hospitalization days, nucleic acid negative conversion time, whether admission to intensive care unit (ICU), turn re-positive on nucleic acid tests and immunoglobulin M (IgM) antibody titer expression between the two groups, but immunoglobulin G (IgG) antibody titer in adenovirus group was higher than that in inactivated group (g/L: 229.67±26.13 vs. 194.33±61.56, P = 0.020). There were also no significant differences in laboratory examinations, hospitalization days, nucleic acid negative conversion time, turn re-positive on nucleic acid tests and Novel coronavirus antibody titers expression of the patients with booster shots between the inactivated vaccine group and the adenovirus vaccine group.

CONCLUSIONS: The protection of inactivated virus vaccine is equivalent to adenovirus vaccine in patients with underlying disease Omicron variant infection, and the titer of IgG antibody in patients with adenovirus vaccine is higher than that in patients with inactivated virus vaccine after one week of recovery.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Xu H, Wang J, Gao H, et al. [Analysis of clinical characteristics of patients with different vaccines and underlying diseases infected with novel coronavirus Omicron variant]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35924509. doi:10.3760/cma.j.cn121430-20220415-00378

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。